Plate size reduction surgery for the Baerveldt 350-mm² glaucoma implant for postoperative motor disturbance

A case report

Hirotaka Tanabe, MD, PhD*, Shunsuke Nakakura, MD, PhD, Asuka Noguchi, MD, Hitoshi Tabuchi, MD, PhD, Yoshiaki Kiuchi, MD, PhD

Abstract

Rationale: Diplopia due to ocular motility disturbance is a common complication after glaucoma drainage device (GDD) surgery. The treatment options include prescription prism glasses, strabismus surgery or GDD removal. However, to the best of our knowledge, GDD size reduction surgery has not been reported.

Patient concerns and diagnoses: An 83-year-old woman diagnosed with primary open angle glaucoma was referred to Tsukazaki Hospital due to uncontrolled intraocular pressure (IOP) in December 2015. We performed an EXPRESS shunt surgery on both eyes in January 2016 and a needling procedure on the left eye in May 2017. Thereafter, because IOP in her left eye remained high, we performed Baerveldt 350-mm² implantation in her inferotemporal area by placing the tube at the sulcus on December 3, 2017. The next day, 4Δ hypertropia (HT) was detected in the left eye in alternate cover testing in primary gaze, and diplopia in the inferotemporal direction was demonstrated. Although IOP was controlled well between 15 and 20 mmHg in her left eye, diplopia did not improve.

Interventions: Three weeks later, we performed a plate size reduction surgery for the Baerveldt 350-mm² implant. In this procedure, we cut and removed the plates placed beneath the lateral rectus muscle and inferior rectus muscle, which were thought to be responsible for diplopia.

Outcomes: Diplopia improved subjectively, but there was no drastic objective change. We prescribed prism glasses (3Δ base down for the left eye) for remaining mild diplopia. On January 21, 2019, significant objective improvement (2Δ HT with less ocular motor dysfunction demonstrated in the Hess chart) was finally observed.

Lessons: Early plate size reduction surgery, which was not immediately but ultimately effective in improving motor disturbance in our case, could be a potential option to relieve operation-induced motor disturbance. However, notably, tube shunt surgery has the risk of motility disturbances, which might require additional treatment.

Abbreviations: ABC = Ahmed Baerveldt Comparison, APCT = alternate cover testing, BD = base down, GDD = glaucoma drainage device, HT = hypertropia, IOP = intraocular pressure, TVT = tube vs trabeculectomy.

Keywords: Baerveldt, diplopia, glaucoma, motor disturbance

1. Introduction

Diplopia due to ocular motility disturbance is a common complication after glaucoma drainage device (GDD) surgery. The Baerveldt implant is a major GDD device that is effective in controlling intraocular pressure (IOP) because of the greater surface area for passive diffusion. However, the incidence of persistent postoperative strabismus associated with the Baerveldt implant ranges from 2.1% to 77% and that of diplopia from 1.4 to 37% in case series.[1–7] In a prospective randomized clinical trial, the incidence of postoperative strabismus associated with the Baerveldt implant was 9.9% and that of diplopia was 5% in the Tube vs trabeculectomy (TVT) study.[8] Additionally, the incidence of diplopia was 2.8% in the Ahmed Baerveldt Comparison (ABC) study.[9] The hypothesized cause of diplopia is mechanical disturbance attributable to the size of the plate, size of the resultant bleb and postoperative adhesion of the surrounding tissue of the rectus muscles.[10–13] The treatment
options for postoperative diplopia after GDD surgery include prescription prism glasses, strabismus surgery or GDD removal. However, to the best of our knowledge, GDD size reduction surgery has not been reported. The present report describes a plate size reduction surgery for a Baerveldt 350-mm² glaucoma implant performed in a patient who experienced postoperative ocular motility disturbance after Baerveldt 350-mm² implantation surgery. Additionally, we reviewed previous reports on treatment of diplopia induced by glaucoma implant surgery. This case report was approved by the Research Ethics Committee of Sanokai Tsukazaki Hospital (Himeji, Japan), and the patient provided informed consent for publication of the case.

2. Case report

An 83-year-old woman diagnosed with primary open angle glaucoma was referred to Tsukazaki Hospital due to uncontrolled ocular pressure in December 2015. At the first visit, the IOP was 28 mmHg in both eyes under maximum anti-glaucoma eyedrop treatment. The mean deviation given by Humphrey Visual Field Analyzer (30–2 program) was –23.86 dB in the right eye and –16.31 dB in the left eye. We performed an EXPRESS shunt surgery on both eyes in the superotemporal area in January 2016 and a needling procedure on the left eye in May 2017. Thereafter, IOP in her left eye remained high (22 mmHg with the use of 2 types of anti-glaucoma eyedrops). Therefore, we performed Baerveldt 350-mm² implantation at her inferotemporal area, placing the tube at the sulcus on December 3, 2017. The next day, 4 Δ hypertropia (HT) was detected in alternate cover testing (APCT) with prism measurement in primary gaze, and significant ocular motility disturbance caused diplopia in gaze to the quadrant direction from inferior to temporal in which the Baerveldt 350-mm² was implanted. Although the IOP was controlled well between 15 and 20 mmHg in her left eye, diplopia did not improve for 3 weeks. The Hess chart suggested persistent motor disturbance of both inferotemporal and supronasal directions (Fig. 1A), which could be attributed to the following reasons: motor disturbance in the inferotemporal direction due to the large size of the Baerveldt implant and motor disturbance in the supronasal direction due to muscle contraction of the rectus muscles under which the Baerveldt implant was placed. On December 23, 2017, we performed a plate reduction surgery for the Baerveldt 350-mm² glaucoma implant. In this procedure, we first confirmed the resistance to both inferotemporal and supronasal directions and the absence of apparent adhesions and scar tissues. Then, we cut and removed the plates placed beneath the lateral rectus muscle and inferior rectus muscle, which were thought to be responsible for diplopia (Fig. 2A–E). After the procedure, diplopia improved subjectively, but there was no drastic objective change with remaining 4 Δ HT in APCT in primary gaze. We prescribed prism glasses (3 Δ base down [BD] for the left eye) for remaining mild diplopia for this patient. Thereafter, IOP was controlled well between 13 and 15 mmHg in her left eye with only topical Dorzolamide 2%. On January 21, 2019, 1 year after the operation, significant objective improvement (2 Δ HT in APCT with less ocular motor dysfunction demonstrated in the Hess chart (Fig. 1B)) was finally observed.

3. Discussion

We reported the case of a patient who developed postoperative diplopia after undergoing Baerveldt 350-mm² glaucoma implantation surgery wherein an earlier Baerveldt plate reduction surgery was not immediately but ultimately effective in improving motor disturbance. The mechanism of diplopia induced by mechanical disturbance was discussed in detail by Muñoz and Parrish.[10] If a large bleb displaces the muscle away from the sclera, the muscle will be stretched and moved to a higher length-tension curve and affect motility to a degree.[11,12] Beyond the range of normal elasticity, the extraocular muscles become stiff and act as a passive restraint. A crowding effect from a large bleb around a glaucoma implant with limited extraocular motility induces persistent diplopia.[13,14] The limited movement in the direction of a glaucoma implant was also described in association with the Molteno implant and is related to a posterior fixation effect induced by scarring between the muscle belly and sclera behind the implant.[13] Thus, the hypothesized cause of diplopia is mechanical disturbance attributable to the size of the plate, size of the resultant bleb and postoperative adhesion of the surrounding tissue of the rectus muscles.[10–15] In the present case, because diplopia occurred the day after Baerveldt implantation and continued for 3 weeks, we speculated that the main causes were the mechanical disturbance induced by the large size of the plate and muscle contraction of the rectus muscles under which the Baerveldt was implanted rather than postoperative adhesion due to a crowding effect or temporal muscle edema.

The surface area of encapsulation around a glaucoma drainage implant is directly proportional to the end plate size. Therefore, the degree of IOP reduction achieved postoperatively is also directly proportional to implant size.[16] Owing to the larger surface area of Baerveldt devices, they have become one of the most effective devices in controlling IOP. However, there appears to be an upper limit to plate size beyond which an increase in surface area may not improve pressure control and may even detrimentally affect surgical outcomes. There was no significant difference in surgical success and visual outcomes between the 350-mm² and 500-mm² Baerveldt glaucoma implants[17] and between the 250-mm² and 350-mm² Baerveldt glaucoma implants[18]; additionally, there was a lower success rate with the 500-mm² Baerveldt than with the 350-mm² implant in a longer follow-up.[6] Although the rate of strabismus after 2 types of Baerveldt implantation was not significantly different, that is, 16%[17] and 20%[6] in the Baerveldt 350-mm² and 19%[6,17] in the Baerveldt 500-mm², or the rate of diplopia (2.7% in the Baerveldt 250-mm² and 3.8% in the Baerveldt 350-mm²),[18] Sun et al[19] demonstrated that GDDs with a larger plate area (Baerveldt 350) had a higher frequency of diplopia (31%) than did GDDs with a smaller plate area (Baerveldt 250 or Ahmed; 11%), which was mainly attributed to the difference in implant size. Similarly, it was also speculated that the Ahmed 184-mm² valve induced fewer motility disturbances than did the double-plate Molteno 270-mm² or the Baerveldt 350-mm² implant because of its smaller surface area.[20–22] Currently, the Baerveldt 500-mm² is not produced by the manufacturer based on the results of many clinical studies. The Baerveldt is now equipped with fenestrations in the end plate, allowing the growth of fibrous bands through the plate to reduce bleb height. Although the incidence of postoperative diplopia has been decreased by these modifications, diplopia remains a major complication that we must be aware of.

Finally, we reviewed the previous reports on treatment of diplopia due to glaucoma implant surgery. Smith et al[7] reported that the removal of the Baerveldt 350-mm² significantly improved diplopia in all 5 cases (replaced with double-plate
Molteno implants in 4 cases and trabeculectomy after the removal in 1 case), but all the other interventions including botulinum injections in 1 case and prescription of prism glasses in 22 cases were only temporarily effective for diplopia and permanent diplopia did not resolve spontaneously in any of those cases. The authors used the old type of Baerveldt implant, which was not equipped with fenestrations in the end plate that allow the growth of fibrous bands through the plate to reduce bleb height; the use of this older implant could partially explain the lack of spontaneous resolution of diplopia. Muñoz and Parrish reported stable diplopia by observation in 4 small cases and commented on the difficulty of obtaining satisfactory results with prism glasses.[11] These authors also mentioned that if strabismus surgery is performed, because it carries the risk of compromising a functioning drainage device by inducing scar tissue, the possibility of surgery in the fellow eye is often reluctantly accepted by the patient.[11] Lloyd et al.[17] reported that although strabismus resolved in some eyes, 6 out of 13 patients underwent muscle surgery to correct motility dysfunction or diplopia. Sun et al.[19] reported that diplopia resolved in 1 and improved in 2 out of 11 post-GDD binocular diplopia patients by observation. The authors noted that the diplopia of these patients started immediately following tube opening and improved over 1 month.[19] Roizen et al.[20] reported 7 patients with severe limitation to ocular rotations and incomitant strabismus who underwent strabismus surgery on an eye containing an implant and 2 patients with mild limitation to ocular rotations in the involved eye who underwent surgery on the contralateral eye. As a result, diplopia in the primary position was eliminated in 5 patients and markedly improved in 3 patients.[20] The authors
confirmed all patients had a large fibrous capsule surrounding the implant plate, adjacent muscles, and sclera; additionally, IOP was not elevated postoperatively in all cases. Rosenbaum and Santiago commented that nonsurgical conservative management consists of observation, prisms, and chemodenervation, but prisms are of limited use because of incomitance or the large angle of the deviation common in postoperative strabismus after GDD implantation. Moreover, the authors noted that surgical management includes strabismus surgery, removal of the implant and replacement of the implant with a smaller device. Additionally, in strabismus surgery, a muscle recession procedure is preferred over a muscle resection or muscle transposition procedure because of the reduced possibility of postoperative motor restriction or difficulty induced by the implant encroaching on the surgical field and sites of muscle attachment.

This study has some limitations. Although there are no articles on the internet (PubMed, etc), plate revision, including its resection, could be a known intervention for postoperative diplopia following Baerveldt implantation to some clinicians. Even if this intervention is known to clinicians, our report is still worthwhile to the public as useful information that a glaucoma surgeon should know. In addition, the strabismus could have resolved without intervention, as it often does. However, no interventions could also lead to no improvement in postoperative strabismus. Thus, we should provide all possible treatment options to patients.

We reduced the size of the Baerveldt 350-mm² by cutting and partially removing the plate, which was just beneath the rectus muscles. To the best of our knowledge, GDD size reduction surgery has not been previously reported. Although diplopia was relieved both subjectively and objectively, no drastic improvement was immediately observed, and we prescribed prism glasses for remaining mild diplopia during follow-up. However, 1 year after the operation, significant objective improvement was finally observed.

4. Conclusion

We reported a case of plate reduction surgery for a Baerveldt 350-mm² glaucoma implant for postoperative motor disturbance. Early plate size reduction surgery, which was not immediately but ultimately effective in improving motor disturbance in our case, could be a potential option to relieve operation-induced motor disturbance. However, notably, tube shunt surgery has the risk of motility disturbances, which might require additional treatment.

Acknowledgments

We thank all the staff of Tsukazaki Hospital who were involved in this study.

Author contributions

Conceptualization: Hirotaka Tanabe, Shunsuke Nakakura.

Investigation: Hirotaka Tanabe, Shunsuke Nakakura.

Project administration: Hitoshi Tabuchi.

Resources: Shunsuke Nakakura, Asuka Noguchi.

Supervision: Hirotaka Tanabe, Shunsuke Nakakura, Yoshiaki Kiuchi.

Validation: Hirotaka Tanabe, Shunsuke Nakakura, Yoshiaki Kiuchi.

Writing – original draft: Hirotaka Tanabe.

Writing – review & editing: Hirotaka Tanabe, Shunsuke Nakakura, Yoshiaki Kiuchi.

Hirotaka Tanabe orcid: 0000-0002-1948-7408.

References

[1] Lloyd MA, Baerveldt G, Heuer DK, et al. Initial clinical experience with the Baerveldt implant in complicated glaucomas. Ophthalmology 1994;101:460–50.

[2] Harbick KH, Sudoni PA, Budenz DL, et al. Outcomes of inferonasal Baerveldt glaucoma drainage implant surgery. J Glaucoma 2006;15:7–12.

[3] Krishna R, Godfrey DG, Budenz DL, et al. Intermediate-term outcomes of 350-mm² Baerveldt glaucoma implants. Ophthalmology 2004;110:621–6.

[4] Tsai JC, Johnson CC, Dietrich MS. The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma: a single-surgeon comparison of outcome. Ophthalmology 2003;110:1814–21.

[5] Roy S, Ravinet E, Mermoud A. Baerveldt implant in refractory glaucoma: long-term results and factors influencing outcome. Int Ophthalmol 2001;24:93–100.
[6] Britt MT, LaBree LD, Lloyd MA, et al. Randomized clinical trial of the 350-mm² versus the 500-mm² Baerveldt implant: longer term results: is bigger better? Ophthalmology 1999;106:2312–8.

[7] Smith SL, Starita RJ, Fellman RL, et al. Early clinical experience with the Baerveldt 350-mm² glaucoma implant and associated extraocular muscle imbalance. Ophthalmology 1993;100:914–8.

[8] Gedde SJ, Herrdon LW, Brands Jd, et al. Postoperative complications in the Tube versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol 2012;153:804–14.

[9] Barton K, Feuer WJ, Budenz DL, et al. Three-year treatment outcomes in the Ahmed Baerveldt comparison study. Ophthalmology 2014;121:1547–57.

[10] Munoz M, Parrish RK2nd. Strabismus following implantation of Baerveldt drainage devices. Arch Ophthalmol 1993;111:1096–9.

[11] Scott A. Extraocular muscle forces in strabismus. In: Bach-Y-Rita P, Collins C, Hyde J, eds., Orlando, Fla: Academic Press Inc, 1971:327–42.

[12] Wright KW. The fat adherence syndrome and strabismus after retina surgery. Ophthalmology 1986;93:413–5.

[13] Ball SF, Ellis GSJr, Herrington RG, et al. Brown’s superior oblique tendon syndrome after Baerveldt glaucoma implant. Arch Ophthalmol 1992;110:1368.

[14] Wilson-Holt N, Franks W, Nourredin B, et al. Hypertropia following insertion of inferiorly sited double-plate Molteno tubes. Eye (Lond) 1992;6:515–20.

[15] Christmann LM, Wilson ME. Motility disturbances after Molteno implants. J Pediatr Ophthalmol Strabismus 1992;29:44–8.

[16] Schwartz KS, Lee RK, Gedde Sj. Glaucoma drainage implants: a critical comparison of types. Curr Opin Ophthalmol 2006;17:181–9.

[17] Lloyd MA, Baerveldt G, Fellenbaum PS, et al. Intermediate-term results of a randomized clinical trial of the 350- versus the 500-mm² Baerveldt implant. Ophthalmology 1994;101:1456–63.

[18] Allan El, Khaimi MA, Jones JM, et al. Long-term efficacy of the Baerveldt 250 mm² compared with the Baerveldt 350 mm² implant. Ophthalmology 2015;122:486–93.

[19] Sun PY, Leske DA, Holmes JM, et al. Diplopia in medically and surgically treated patients with glaucoma. Ophthalmology 2017;124:257–62.

[20] Roizen A, Ela-Dalman N, Velez FG, et al. Surgical treatment of strabismus secondary to glaucoma drainage device. Arch Ophthalmol 2008;126:480–6.

[21] Rosenbaum AL, Santiago AP. Rosenbaum AL, Santiago AP. Strabismus after glaucoma implant procedures. Clinical Strabismus Management Philadelphia, PA: WB Saunders Co; 1999:304–7.

[22] Damji K, Freedman S, Moroi S. Allingham RR, Shields MB, Damji KF, Freedman S, Moroi S, et al. Drainage implant surgery. Shields’ Textbook of Glaucoma. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:610–21.